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The transplantation of pancreatic islets is an innovative and intriguing therapeutic 
option for the long term treatment of type-1 diabetes (Remuzzi et al., 2009). Unfor-
tunately, their clinical feasibility is limited by the great number of islets necessary 
to achieve glycaemic control and their short survival. A possible means to improve 
the performance of this technique can be represented by Mesenchymal Stem Cells 
(MSCs), adult stem cells alrady known to support the survival of different cellular 
populations (Scuteri et al., 2014). In this work the ability of Mesenchymal Stem Cells 
(MSCs) to improve the feasibility of this approach was verified into an in vivo model 
represented by Streptozotocin-induced diabetic rats. 
We compared 5 different groups (8 rats/group): a) healthy controls; b) Diabetic 
rats; c) Diabetic rats transplanted with pancreatic islets (3000); d) Diabetic rats co-
transplanted with pancreatic islets (2000) and MSCs (106); Diabetic rats treated with 
MSCs (106). Transplantations were performed after the assessment of neuropathic 
signs, represented by a decreased Nerve Conduction Velocity (NCV) and an impair-
ment of nociceptive thermal and mechanical thresholds. The same parameters were 
evaluated two months after the transplantation.
Diabetic rats transplanted only with pancreatic islets, or co-transplanted with 
MSCs and a suboptimal number of pancreatic islets, showed a significant glycae-
mia value reduction, an improvement of thermal and mechanical sensitivity, and an 
improvement of NCV with respect to diabetic-untreated rats. No differences were 
observed between diabetic rats and diabetic rats treated with only MSCs. 
In conclusion, we demonstrated that co-transplantation with MSCs reduces 
the number of pancreatic islets needed to reach glycaemic control, and induces the 
regression of painful neuropathy signs, thus ameliorating diabetes complications 
management. 
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